vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Alarm.com Holdings, Inc. (ALRM). Click either name above to swap in a different company.
Alarm.com Holdings, Inc. is the larger business by last-quarter revenue ($261.7M vs $139.2M, roughly 1.9× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 13.2%, a 22.3% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 8.0%). Alarm.com Holdings, Inc. produced more free cash flow last quarter ($35.1M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 8.3%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Alarm.com, Inc. is an American technology company that provides cloud-based services for remote control, home automation, and alarm monitoring services. The company was founded in 2000 as a spinoff from MicroStrategy. The company is based in Tysons, Virginia.
ADMA vs ALRM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $261.7M |
| Net Profit | $49.4M | $34.6M |
| Gross Margin | 63.8% | 66.0% |
| Operating Margin | 45.1% | 13.4% |
| Net Margin | 35.5% | 13.2% |
| Revenue YoY | 18.4% | 8.0% |
| Net Profit YoY | -55.9% | 14.8% |
| EPS (diluted) | $0.20 | $0.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $261.7M | ||
| Q3 25 | $134.2M | $256.4M | ||
| Q2 25 | $122.0M | $254.3M | ||
| Q1 25 | $114.8M | $238.8M | ||
| Q4 24 | $117.5M | $242.2M | ||
| Q3 24 | $119.8M | $240.5M | ||
| Q2 24 | $107.2M | $233.8M | ||
| Q1 24 | $81.9M | $223.3M |
| Q4 25 | $49.4M | $34.6M | ||
| Q3 25 | $36.4M | $35.1M | ||
| Q2 25 | $34.2M | $34.2M | ||
| Q1 25 | $26.9M | $27.7M | ||
| Q4 24 | $111.9M | $30.1M | ||
| Q3 24 | $35.9M | $36.7M | ||
| Q2 24 | $32.1M | $33.5M | ||
| Q1 24 | $17.8M | $23.6M |
| Q4 25 | 63.8% | 66.0% | ||
| Q3 25 | 56.3% | 65.8% | ||
| Q2 25 | 55.1% | 65.6% | ||
| Q1 25 | 53.2% | 67.2% | ||
| Q4 24 | 53.9% | 65.5% | ||
| Q3 24 | 49.8% | 64.8% | ||
| Q2 24 | 53.6% | 65.2% | ||
| Q1 24 | 47.8% | 65.7% |
| Q4 25 | 45.1% | 13.4% | ||
| Q3 25 | 38.0% | 14.4% | ||
| Q2 25 | 35.1% | 12.6% | ||
| Q1 25 | 30.4% | 12.4% | ||
| Q4 24 | 32.6% | 12.7% | ||
| Q3 24 | 33.1% | 13.8% | ||
| Q2 24 | 36.6% | 11.0% | ||
| Q1 24 | 26.7% | 8.4% |
| Q4 25 | 35.5% | 13.2% | ||
| Q3 25 | 27.1% | 13.7% | ||
| Q2 25 | 28.1% | 13.5% | ||
| Q1 25 | 23.4% | 11.6% | ||
| Q4 24 | 95.2% | 12.4% | ||
| Q3 24 | 30.0% | 15.3% | ||
| Q2 24 | 29.9% | 14.3% | ||
| Q1 24 | 21.7% | 10.6% |
| Q4 25 | $0.20 | $0.66 | ||
| Q3 25 | $0.15 | $0.65 | ||
| Q2 25 | $0.14 | $0.63 | ||
| Q1 25 | $0.11 | $0.52 | ||
| Q4 24 | $0.45 | $0.56 | ||
| Q3 24 | $0.15 | $0.67 | ||
| Q2 24 | $0.13 | $0.62 | ||
| Q1 24 | $0.08 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $960.6M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $848.2M |
| Total Assets | $624.2M | $2.1B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $960.6M | ||
| Q3 25 | $61.4M | $1.1B | ||
| Q2 25 | $90.3M | $1.0B | ||
| Q1 25 | $71.6M | $1.2B | ||
| Q4 24 | $103.1M | $1.2B | ||
| Q3 24 | $86.7M | $1.2B | ||
| Q2 24 | $88.2M | $1.1B | ||
| Q1 24 | $45.3M | $747.9M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $848.2M | ||
| Q3 25 | $431.2M | $827.2M | ||
| Q2 25 | $398.3M | $797.3M | ||
| Q1 25 | $373.4M | $759.6M | ||
| Q4 24 | $349.0M | $726.5M | ||
| Q3 24 | $231.9M | $690.3M | ||
| Q2 24 | $188.3M | $645.5M | ||
| Q1 24 | $153.7M | $728.1M |
| Q4 25 | $624.2M | $2.1B | ||
| Q3 25 | $568.7M | $2.1B | ||
| Q2 25 | $558.4M | $2.1B | ||
| Q1 25 | $510.6M | $2.1B | ||
| Q4 24 | $488.7M | $2.0B | ||
| Q3 24 | $390.6M | $2.0B | ||
| Q2 24 | $376.4M | $1.9B | ||
| Q1 24 | $350.9M | $1.5B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $35.9M |
| Free Cash FlowOCF − Capex | $34.6M | $35.1M |
| FCF MarginFCF / Revenue | 24.8% | 13.4% |
| Capex IntensityCapex / Revenue | 0.8% | 0.3% |
| Cash ConversionOCF / Net Profit | 0.72× | 1.04× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $137.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $35.9M | ||
| Q3 25 | $13.3M | $70.6M | ||
| Q2 25 | $21.1M | $22.7M | ||
| Q1 25 | $-19.7M | $24.1M | ||
| Q4 24 | $50.2M | $56.3M | ||
| Q3 24 | $25.0M | $77.3M | ||
| Q2 24 | $45.6M | $23.0M | ||
| Q1 24 | $-2.2M | $49.9M |
| Q4 25 | $34.6M | $35.1M | ||
| Q3 25 | $-1.1M | $65.9M | ||
| Q2 25 | $18.7M | $18.2M | ||
| Q1 25 | $-24.4M | $17.9M | ||
| Q4 24 | $47.5M | $54.0M | ||
| Q3 24 | $24.0M | $74.5M | ||
| Q2 24 | $43.6M | $21.0M | ||
| Q1 24 | $-4.6M | $46.8M |
| Q4 25 | 24.8% | 13.4% | ||
| Q3 25 | -0.8% | 25.7% | ||
| Q2 25 | 15.3% | 7.1% | ||
| Q1 25 | -21.2% | 7.5% | ||
| Q4 24 | 40.4% | 22.3% | ||
| Q3 24 | 20.0% | 31.0% | ||
| Q2 24 | 40.7% | 9.0% | ||
| Q1 24 | -5.6% | 21.0% |
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 10.7% | 1.9% | ||
| Q2 25 | 2.0% | 1.8% | ||
| Q1 25 | 4.1% | 2.6% | ||
| Q4 24 | 2.3% | 0.9% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 1.9% | 0.9% | ||
| Q1 24 | 2.9% | 1.4% |
| Q4 25 | 0.72× | 1.04× | ||
| Q3 25 | 0.36× | 2.01× | ||
| Q2 25 | 0.62× | 0.66× | ||
| Q1 25 | -0.73× | 0.87× | ||
| Q4 24 | 0.45× | 1.87× | ||
| Q3 24 | 0.70× | 2.11× | ||
| Q2 24 | 1.42× | 0.69× | ||
| Q1 24 | -0.12× | 2.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
ALRM
| License And Service | $180.2M | 69% |
| Hardwareand Other Revenue | $81.4M | 31% |
